Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05934539 | ALG.APV-527 First-in-human Study | unknown | Phase 1 / Phase 2 | 56 | Aptevo TherapeuticsINDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05915481 | Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors(SCARCE) | unknown | Phase 1 / Phase 2 | 60 | Peking University Third HospitalOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05268666 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05904457 | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer(BRISK) | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05869240 | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 388 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05794477 | A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05207787 | Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 306 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05862831 | Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 285 | Biotheus Inc.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04571892 | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 58 | Shanghai East HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05785728 | A Study of DB-1202 Monotherapy in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | DualityBio Inc.INDUSTRY | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05790447 | Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04522284 | PRECISE CURATE.AI Pilot Clinical Trial | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05434299 | A Study of TFX05-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 36 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | unknown | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05748938 | A Study of RD14-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05740215 | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 158 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05642949 | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 400 | Minghui Pharmaceutical Pty LtdINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05372120 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | unknown | Phase 2 | 200 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jan 4, 2023 | clinicaltrials |
| NCT05214976 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | unknown | Phase 2 | 64 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04614740 | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05645315 | Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 127 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04450901 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Y Biologics Inc.INDUSTRY | 3 | Dec 5, 2022 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05457517 | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 49 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05530200 | PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. | unknown | Phase 2 | 56 | Second Affiliated Hospital of Soochow UniversityOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05527821 | Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors | unknown | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05528406 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation | unknown | Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Sep 6, 2022 | clinicaltrials |
| NCT05524194 | 6MW3511 in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 272 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05512780 | Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer | unknown | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05508659 | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 128 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT05505877 | Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 160 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04892498 | Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) | unknown | Phase 2 | 66 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05478785 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT03758664 | Clinical Study of ICP-192 in Solid Tumors Patients | unknown | Phase 1 / Phase 2 | 56 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05349409 | A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers | unknown | Phase 2 | 212 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05216965 | A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 208 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04082910 | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05322720 | HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | unknown | Phase 2 | 50 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 7, 2023source: clinicaltrials